What I see going forward is Nader’s percentage share of

New Post Public Reply Private Reply Replies (1) Message Board
Goosebumps
618
What I see going forward is Nader’s percentage share of running the company diminishing over time. Nader said around a year ago that he has considered a slower personal roll in the company. Nader said that Dr. Kelly would hire all new employees and further the International Advisory Board. Dr. Kelly has done a wonderful job so far and hit it out of the park with his last few hires.

A great leader is a person that recognizes his weaknesses and hires people to overcome such weaknesses. If you interviewed CEO’s they would tell you that the best things they ever did was to hire the right people and that’s where their success comes from. No one can do it all. Our time as a company with many many employees to do all the needed tasks required to be a big pharmaceutical company is as close as our first approval and revenue. We will grow then for sure.

I would not like to change leadership of Cytodyn at this point in time. It could delay us years and lose the relationships we now share with the FDA. You may not believe that Nader has a great relationship with the FDA but I believe he does. He gives them their due respect and that goes a long way in any relationship. Nader is smart that way.

You can hate or blame Nader all you want. But he has got us this far at a minimal cost and minimal time compared to the averages of biotechs looking for drug approvals. This is the reason we are in the position we are currently. Close to approval. With a change of direction to Covid is and was a huge directional change. Most of and/if not all were NOT supportive of his change of direction.

Fact is we are most likely to get our first approval in Covid. Looks like a genius move now and he took heat for it. Nader has made great decisions in funding and been very respectful of dilution. Great leadership quality is a conservative approach financially. Nader has that. We should be thankful.

I will support a leader like Nader all day long for the above reasons. He has recognized his mistakes and made changes and that is huge also. Nader has all the qualities we need to get us over the finish line. A lot of the items awaiting our finish are just out of our control and anyone’s control. No matter who is CEO. It’s up to the drug to prove itself out and for regulatory agencies to be aware of it. Nader will be there for us to smile and complement the FDA just like a great CEO would be there.

This is why he is the right person for the CEO of Cytodyn now and until he steps back further. There should be no doubt about that. Yet people will push their agenda and try to discredit Nader.

Listen to them and make your own opinion and review the facts about our CEO. I believe you will find far more important reasons to have Nader than to have someone else leading this company. over the finish line. But all opinions do matter. Do a proper pro/con assessment and have your own opinion.
2

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

USPS Honors 150 Years of the U.S. Coast Guard Academy

Updated Category News Views 0

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

Continue Reading
D-Wave Faces Legal Questions After CFO Exit and Losses

Updated Category News Views 1

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Continue Reading
New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Updated Category News Views 3

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 7

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 4

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
Ajman Spotlights Tourism at Arabian Travel Market 2026

Updated Category News Views 2

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Continue Reading
Delhi Pushes Innovation Against Dryland Challenges

Updated Category News Views 5

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Continue Reading
Damp or Dry: The Battle for Healthy Air in Colorado

Updated Category News Views 3

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 7

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading
Protecting Teeth: Insights from Endodontist Dr. Joubert

Updated Category News Views 3

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Continue Reading

Top 5 Most Recently Viewed Articles

Toll Brothers Unveils Stunning New Homes in Chapel Oaks

Updated Category News Views 200

Exciting New Model Homes at Chapel Oaks Community CHAPEL HILL, N.C. – Toll Brothers, Inc. (NYSE: TOL), a prominent name in luxury home construction, has recently announced the opening of their latest model home at the Chapel Oaks community. This new community marks a significant addition to their portfolio in the Raleigh area, providing prospective homeowners with...

Continue Reading
Harbour BioMed Projects Significant Profit Growth for 2025

Updated Category News Views 117

Positive Profit Alert for Harbour BioMed Harbour BioMed, a prominent global biopharmaceutical company, recently announced optimistic profit projections for the year ending December 31, 2025. This announcement comes as a part of their continuous commitment to pioneering antibody therapeutics within the fields of immunology and oncology. Financial Expectations and Growth...

Continue Reading
Watsco Prepares for Significant Q2 Earnings Call This Summer

Updated Category News Views 112

Watsco's Upcoming Second Quarter Earnings Call Watsco, Inc. (NYSE: WSO), a leader in the distribution of heating, air conditioning, and refrigeration (HVAC/R) products, is all set to host its anticipated second quarter earnings call. This event will take place soon, promising insights into the company’s performance and future projections. Investors and analysts alike...

Continue Reading
Innovative AI Technology by Garrett Metal Detectors Transformed

Updated Category News Views 140

Groundbreaking Insights into AI Innovations in Security Detection Located in Texas, Garrett Metal Detectors has introduced a revolutionary product in the field of security technology. The company recently unveiled their latest innovation: the Paragon walk-through metal detector, which is now powered by Clarity, an advanced AI-driven development platform. This platform...

Continue Reading
ProVen VCT plc Announces Significant Director Share Purchases

Updated Category News Views 121

ProVen VCT plc: Recent Director Shareholding Activity ProVen VCT plc has made headlines with recent transactions involving its directors. The company disclosed that several of its directors have bought ordinary shares of 10 pence each recently. This activity reflects confidence in the company's performance and future prospects. Details of Director Transactions James...

Continue Reading